AnHeart Therapeutics
Dr. Andrés Cervantes is a Professor of Medicine at the University of Valencia, Spain. He got his training in Medical Oncology at the University Hospital in Valencia. After completing his clinical training he got a research fellowship for two years at the Free University Hospital in Amsterdam, where he obtained his Ph.D. degree with work on multidrug resistance in the Cellular Pharmacology Lab of this institution.
Dr. Cervantes serves as Head of the Department of Medical Oncology at the University Hospital in Valencia, Spain. He is also the scientific director of the Institute of Health Research INCLIVA, one of the nationally accredited research institutes in Spain. His main areas of research and clinical interest are gastrointestinal and gynecologic malignancies as well as phase 1 and early clinical trials and new drug development. He is a dedicated clinical investigator for rectal cancer, a topic in which he has developed several publications concerning the quality of multidisciplinary teamwork as well as quality assessment of mesorectal surgery, how to improve on the optimal selection of initial therapy, and specifically how to approach upper third rectal cancer. He is also responsible for a translational research lab, mainly working on liquid biopsies and in the molecular classification of gastrointestinal malignancies. He is the author of more than two hundred research articles and educational papers published in peer-reviewed journals. He is also one of the Editors in chief of Cancer Treatment Reviews. Since January 2014, he is also Associate Editor for Gastrointestinal Cancer in the Annals of Oncology.
This person is not in the org chart
This person is not in any offices
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.